PMA device
G5 Mobile Continuous Glucose Monitoring System
Dexcom, Inc. · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Aug 19, 2015, newest Jan 9, 2024Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
4
Naming "G5 Mobile"
MAUDE reports
333,318
Brand "G5 Mobile", since 2015
PubMed studies
14
Mentioning "G5 Mobile"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing G5 Mobile Continuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- G5 Mobile Continuous Glucose Monitoring System, G6 Continuous Glucose Monitoring System, G7 Continuous Glucose MonitorinPMA supplement
P120005-S091 · Decided Jan 9, 2024 · 55 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
- DEXCOM G5 Mobile Continuous Glucose Monitoring SystemPMA supplement
P120005-S090 · Decided Jan 12, 2023 · 90 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
- Dexcom G5 Mobile Continuous Glucose Monitoring SystemPMA supplement
P120005-S088 · Decided Jan 20, 2022 · 276 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "G5 Mobile", any status and sponsor, newest update first.
- Diabetes Pump With Predictive Low Glucose Suspend Pivotal TrialPivotal-lookingCompleted
Tandem Diabetes Care, Inc.Public (TNDM)
NCT03195140 · 103 participants · Start Aug 11, 2017 · Primary completion Feb 6, 2018
Device: Predictive Low Glucose Suspend · For: Diabetes Mellitus, Type 1
Sites: Palo Alto, California; Santa Barbara, California; Aurora, Colorado · 4 sites in all
Jessa HospitalAcademic, hospital or other
NCT03602963 · 10 participants · Start Jul 9, 2018 · Primary completion Dec 31, 2018
Device: Dexcom G5 Mobile CGM system · For: Type 1 Diabetes Mellitus
Sites: Hasselt, Belgium
- Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)Pivotal-lookingCompleted
Science Consulting in DiabetesNot on our public-company list
NCT02671968 · 141 participants · Start Feb 2016 · Primary completion Jul 14, 2017
Device: Continuous Glucose Monitoring System · For: Diabetes
Sites: Aschaffenburg, Germany; Bad Heilbrunn, Germany; Bad Mergentheim, Germany · 12 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "G5 Mobile", and for the whole product code for context.
This brand
333,318 reports: 330,149 malfunction, 3,144 injury, 25 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
3004753838-2026-262591 · Received Sep 29, 2026 · Event dated Aug 11, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-187735 · Received Jul 2, 2026 · Event dated Jun 3, 2026
Device type: Sensor, Glucose, Invasive, Non-Adjunctive (PQF)
Device problem as coded: Inappropriate or Unexpected Reset
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-125854 · Received Apr 6, 2026 · Event dated Mar 9, 2026
Device type: Sensor, Glucose, Invasive, Non-Adjunctive (PQF)
Device problem as coded: Detachment of Device or Device Component
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1560-2020 · Started Feb 3, 2020
Reason given: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.
Cause as FDA categorized it: Under Investigation by firm · Device type: Sensor, Glucose, Invasive (MDS)
Z-1561-2020 · Started Feb 3, 2020
Reason given: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.
Cause as FDA categorized it: Under Investigation by firm · Device type: Sensor, Glucose, Invasive, Non-Adjunctive (PQF)
Published research
The most relevant PubMed records for "G5 Mobile"[tiab]. The summary above synthesizes these.
- Regulation Catches Up to Reality.
Edelman SV · J Diabetes Sci Technol · 2017
- Comparative Accuracy Analysis of a Real-time and an Intermittent-Scanning Continuous Glucose Monitoring System.
Link M, Kamecke U, Waldenmaier D, et al. · J Diabetes Sci Technol · 2021Research Support, Non-U.S. Gov't
- Impact of Real-Time CGM Data Sharing on Quality of Life in the Caregivers of Adults and Children With Type 1 Diabetes.
Polonsky WH, Fortmann AL · J Diabetes Sci Technol · 2022Research Support, Non-U.S. Gov't
- The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes.
Polonsky WH, Soriano EC, Fortmann AL · Diabetes Technol Ther · 2022Research Support, Non-U.S. Gov't
- Performance and Usability of Three Systems for Continuous Glucose Monitoring in Direct Comparison.
Freckmann G, Link M, Kamecke U, et al. · J Diabetes Sci Technol · 2019Comparative Study, Research Support, Non-U.S. Gov't
- Comparing the accuracy of transcutaneous sensor and 90-day implantable glucose sensor.
Boscari F, Vettoretti M, Amato AML, et al. · Nutr Metab Cardiovasc Dis · 2021Clinical Trial, Comparative Study
- Commentary Regarding Shapiro, "Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe?".
Price D · J Diabetes Sci Technol · 2017Comment
- Impact of Real-Time Continuous Glucose Monitoring Data Sharing on Quality of Life and Health Outcomes in Adults with Type 1 Diabetes.
Polonsky WH, Fortmann AL · Diabetes Technol Ther · 2021Research Support, Non-U.S. Gov't
- The Use of Continuous Glucose Monitoring With Remote Monitoring Improves Psychosocial Measures in Parents of Children With Type 1 Diabetes: A Randomized Crossover Trial.
Burckhardt MA, Roberts A, Smith GJ, et al. · Diabetes Care · 2018Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Type-1 Diabetes Patient Decision Simulator for In Silico Testing Safety and Effectiveness of Insulin Treatments.
Vettoretti M, Facchinetti A, Sparacino G, et al. · IEEE Trans Biomed Eng · 2018
- Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
Chaugule S, Graham C · J Med Econ · 2017Randomized Controlled Trial
- Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
Heinemann L, Freckmann G, Ehrmann D, et al. · Lancet · 2018Multicenter Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
- Guardian RtMedtronic Minimed · PMA 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.